About Arbor pharma
Arbor pharma is a Healthcare company based in Atlanta (United States) founded in 2006, and was acquired by Azurity Pharmaceuticals in August 2021. Dose-form innovations for established medicines are developed. Arbor pharma has raised $23.14 million across 7 funding rounds from investors including KKR, Azurity Pharmaceuticals and JW Asset Management. The company has 625 employees. Arbor pharma has completed 1 acquisition, including XenoPort. Arbor pharma offers products and services including Xifyrm and Danziten. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Azurity Pharmaceuticals, Inc.
Company details
Arbor Pharma was founded in 2006 and is headquartered in Atlanta, United States. Operations are centered in the pharmaceutical sector, where novel dose forms of existing medications are developed to address unmet patient needs. Emphasis is placed on scaled and rapid development, strengthened commercial functions, and a workforce guided by principles of clarity, collaboration, empathy, reliability, and simplicity. High-quality medicines are targeted at underserved populations.
- Headquarters Atlanta, United States
- Employees 625
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website arborpharma.com
- Social LinkedIn
- Acquired by Azurity Pharmaceuticals (Aug 2021)
- Legal Name Azurity Pharmaceuticals, Inc
- Total Equity Funding$23.14M (USD)
in 7 rounds
- InvestorsKKR
& 4 more
- Employee Count625
- Investments & Acquisitions
- Acquired by
Products & Services of Arbor pharma
Arbor pharma offers a comprehensive portfolio of products and services, including Xifyrm and Danziten.
Xifyrm is utilized for the management of moderate-to-severe pain in adults as an IV non-steroidal anti-inflammatory drug.
Danziten is employed in oncology treatments, with full prescribing information provided for indications and safety.
Funding Insights of Arbor pharma
Arbor pharma has successfully raised a total of $23.14M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.14M
- Total Rounds 7
- First Round $400,168
(Sep 2006)
- Investors Count 3
All 7 funding rounds of Arbor pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | Series C | – | KKR | – | |
| Feb 2013 | $100M | Debt – Conventional | – | – | – |
| Nov 2010 | $17.3M | Debt – Venture | – | – | |
| Nov 2010 | $17.5M | Series B | – | Signet Healthcare Partners | |
| Apr 2010 | $4.6M | Series A | – | – | – |
| Jan 2009 | $636,255 | Series A | – | – | – |
| Sep 2006 | $400,168 | Seed | – | – | – |
5 investors in total: 4 institutional and 1 angel.
Investors in Arbor pharma
Arbor pharma has secured backing from 5 investors, including venture fund and angel investors. Prominent investors backing the company include KKR, Azurity Pharmaceuticals and JW Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Investment services are offered in healthcare and cannabis sectors. | jwfunds.com | |||
PE firm investing in North America and Europe | signethealthcarepartners.com | New York, United States | ||
JW Jason Wild | Indian angel investor, active in tech startups, based in India. | unknown_7e08f9f5184b4c83b | ||
Generic drugs are manufactured by Azurity Pharmaceuticals in the US. | 1999 | azurity.com | Woburn, United States |
Investor details for Arbor pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arbor pharma
Arbor pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include XenoPort.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biopharmaceutical products for neurological disorders and pain are provided. | xenoport.com | Santa Clara, United States | 1999 | May 2016 | $467M |
Complete acquisition details for Arbor pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Arbor pharma
5 dated milestones of Arbor pharma across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Arbor pharma is founded.
- Funding First funding round of $400K.
- Funding Latest funding round, Series C,.
- Acquisition Acquires XenoPort.
- Exit Acquired by Azurity Pharmaceuticals.
Web traffic of Arbor pharma
Websites that share an audience with Arbor pharma (arborpharma.com).
Websites whose visitors overlap most with Arbor pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| concertpharma.com | 100% | View details | |||
| amneal.com | 100% | 26.8K | #959,075 | View details | |
| acellapharma.com | 100% | 4K | #5,202,055 | View details | |
| camb-labs.com | 99% | View details | |||
| pernixtx.com | 99% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Arbor pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Arbor pharma (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Arbor pharma
Arbor pharma was founded in 2006.
Arbor pharma is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Arbor pharma is a funded company, having raised a total of $23.14M across 7 funding rounds to date. The company's 1st funding round was a Seed of $400.17K, raised on Sep 2006.
Arbor pharma has 625 employees.
Arbor Pharma was founded in 2006 and is headquartered in Atlanta, United States. Operations are centered in the pharmaceutical sector, where novel dose forms of existing medications are developed to address unmet patient needs. Emphasis is placed on scaled and rapid development, strengthened commercial functions, and a workforce guided by principles of clarity, collaboration, empathy, reliability, and simplicity. High-quality medicines are targeted at underserved populations.
Arbor pharma offers Xifyrm and Danziten.
Arbor pharma has made 1 acquisition, including XenoPort.
Arbor pharma has 5 investors. Key investors include KKR, Azurity Pharmaceuticals, JW Asset Management, Signet Healthcare Partners, and Jason Wild.
Arbor pharma operates through Azurity Pharmaceuticals, Inc.
Yes. Arbor pharma was acquired by Azurity Pharmaceuticals in August 2021.